GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Common Stock

GYRE (Gyre Therapeutics) Common Stock : $0.1 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Common Stock?

Gyre Therapeutics's quarterly common stock stayed the same from Jun. 2024 ($0.1 Mil) to Sep. 2024 ($0.1 Mil) but then increased from Sep. 2024 ($0.1 Mil) to Dec. 2024 ($0.1 Mil).

Gyre Therapeutics's annual common stock increased from Dec. 2022 ($0.1 Mil) to Dec. 2023 ($0.1 Mil) and increased from Dec. 2023 ($0.1 Mil) to Dec. 2024 ($0.1 Mil).


Gyre Therapeutics Common Stock Historical Data

The historical data trend for Gyre Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Common Stock Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Common Stock
9.62 0.06 0.08 0.09

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.08 0.09 0.09 0.09 0.09

Gyre Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Gyre Therapeutics Business Description

Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.